- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04671212
Discarded Bone Marrow for Hematology Research
The primary objective of this study is to establish a mechanism to obtain discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals. The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment. It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant.
Secondary objectives
- To develop gene transfer and gene editing strategies as potentially curative therapy for hemoglobinopathies (e.g. sickle cell disease (SCD) and β-thalassemia).
- To develop a drug treatment strategy which elevates the expression of fetal hemoglobin to a potentially curative level for hemoglobinopathies.
- To examine the biology of bone marrow cells isolated from patients with hemoglobinopathies.
Study Overview
Status
Conditions
Detailed Description
The hemoglobinopathies (e.g. sickle cell disease (SCD) and thalassemia) are devastating inherited anemias that shorten and reduce quality of life. The only current curative therapy for SCD is bone marrow transplantation. However, many patients lack access to suitable donors for transplant. Alternative treatments based on gene therapy, gene editing and novel drugs are currently being developed and show great promise for hemoglobinopathies. Gene therapy and gene editing are especially appealing because they eliminate both the need for donors and the potentially devastating side effects of Graft-versus-Host Disease because they take advantage of the patients own cells. In gene therapy approaches, hematopoietic stem and progenitor cells (HSPCs) are collected from a patient and then treated to 'correct' or 'replace' the disease-causing mutation. However, much work remains to develop optimal gene therapy and gene editing protocols, as well as better understand the inherent biology of HSPCs in patients with hemoglobinopathies.
Researchers at St. Jude want to learn how to best manipulate HSPCs from hemoglobinopathy patients with gene therapy and gene editing technologies to achieve optimal gene correction and/or replacement, as well as optimal engraftment of 'corrected' HSPCs after transplantation. St. Jude researchers also seek to test candidate drugs on SCD HSPCs that might ameliorate the symptoms of SCD. Finally, St. Jude researchers seek to thoroughly characterize the basic biology and function of HSPCs isolated from hemoglobinopathy patients.
Bone marrow-containing bone samples that are typically discarded during orthopedic surgery will be saved from hemoglobinopathy patients, as well as non- hemoglobinopathy patients, undergoing these surgeries. These samples will be shipped to the St. Jude Hematology Department for experimental research aimed at addressing the primary and secondary objectives of this protocol.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Shannon McKinney-Freeman, Ph.D.
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Recruiting
- St. Jude Children's Research Hospital
-
Contact:
- Shannon McKinney-Freeman, Ph.D.
- Phone Number: 866-278-5833
- Email: referralinfo@stjude.org
-
Principal Investigator:
- Shannon McKinney-Freeman, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of any age receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
Patients receiving orthopedic surgery for clinical management will be considered for this study if they have the following diagnosis and criteria:
- Homozygous S/S disease or doubly heterozygous for S and β thalassemia who are two years or older are eligible.
- HbE-β- thalassemia or homozygous (severe) β-thalassemia. including those who are transfusion dependent (major) or severely anemic but relatively transfusion independent (intermedia). Diagnostic criteria include standard hematological parameters, red cell indices, hemoglobin electrophoresis and quantitative determination of HbF and HbA2.
Exclusion Criteria:
- Active, acute manifestations of sickle cell disease including painful crisis, acute chest syndrome, cerebrovascular events or active infection.
- Pregnant women will not be eligible for study enrollment
- Inability or unwillingness of the research participant or legal guardian/representative to give written informed consent will preclude enrollment on this research protocol.
- Platelet count < 150,000/mm^3
- Neutrophil count < 2000/mm^3
- Neutrophil count < 1000/mm^3 for patients on hydroxyurea therapy
- Prothrombin Time > 17 seconds
- Partial thromboplastin Time > 43 seconds
- History of excessive bleeding in the context of previous procedures including surgery and dental extractions
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Orthopedic Surgery Patients
Participants receiving orthopedic surgery for clinical management that involve bone marrow containing bone discard.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collection, processing and storage of discarded bone marrow-containing bone samples from hemoglobinopathy, as well as non-hemoglobinopathy individuals.
Time Frame: After completion of sample collection, approximately 10 years
|
Discarded bone marrow-containing bone samples will be collected for use in research; The processing of samples will help to understand how best to manipulate HSPC's from hemoglobinopathy patients with gene therapy and gene technologies in the laboratory environment.
It will also allow us to establish a reservoir of samples that can be studied in the future to assess cellular function and fitness for transplant.
Samples may be subject to comprehensive assessment of hematopoietic activity using tissue culture based assays, as well as molecular profiling studies of global transcriptome and epigenomes.
|
After completion of sample collection, approximately 10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shannon McKinney-Freeman, Ph.D., St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMHR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemoglobinopathies
-
Sohag UniversityNot yet recruitingHemoglobinopathies
-
University Hospital, MontpellierNot yet recruiting
-
University Hospital, Basel, SwitzerlandCompleted
-
Società Italiana Talassemie ed EmoglobinopatieRecruitingMalignacy, HemoglobinopathieItaly
-
HaEmek Medical Center, IsraelCompletedHgb C HemoglobinopathyIsrael
-
Società Italiana Talassemie ed EmoglobinopatieRecruitingHaemoglobinopathiesItaly
-
Children's Hospital of PhiladelphiaActive, not recruitingHemoglobinopathies | Immunodeficiencies | Non Malignant DiseasesUnited States
-
Azienda Ospedaliera V. CervelloUnknownHemoglobinopathiesItaly
-
Masonic Cancer Center, University of MinnesotaRecruitingHemoglobinopathies | Immunodeficiencies | Hematologic DisordersUnited States
-
Bristol-Myers SquibbRecruitingAnemiaThailand, China, Canada, Turkey, Greece, Taiwan, Italy, Hong Kong